Independent U.S. Market Research

Biotech Catalysts, Stock Hubs & U.S. Small/Mid-Cap Research

Merlintrader publishes independent educational research on U.S.-listed biotech and small- and mid-cap stocks, with daily market briefings, FDA and PDUFA tracking, catalyst calendars and dedicated company hubs across biotech, space, defense, AI, cannabis, energy and critical minerals.

Merlintrader’s Daily Briefing

Monday, August 17, 2026, written before the New York open. Asia is trading, Seoul is shut for Liberation Day and the two things that have changed since Friday both arrived overnight. Japan’s second-quarter growth came in at half the expected pace, and vessel traffic through the Strait of Hormuz collapsed over the weekend to a level that makes the shipping question, rather than the negotiation, the measurable one. Underneath both, the rate path has kept drifting: after Friday’s retail sales miss the dollar is softer, Treasuries are firmer and bets on a Federal Reserve increase have thinned again. The heaviest Chinese data of the month is still pending, moved to an afternoon slot. Index levels quoted are Friday, August 14 closes.

Where Monday opens
  • Wall Street — The S&P 500 closed Friday at 7,785.76, down 0.2% from Thursday’s record, with the Dow at 53,732.41 after shedding 107.58 points and the Nasdaq Composite at 26,729.16. The week still ended green for the S&P at 0.4%, a third straight weekly advance, while the Dow finished 0.6% lower and the Nasdaq added 0.1%.Equities
  • The record — Thursday’s session carried the S&P 500 above 7,800 for the first time, with an intraday high of 7,816.70. Friday gave part of it back rather than breaking the trend, and futures came into Monday mixed rather than directional.Equities
  • Asia — Trading was thin and two-sided. The Nikkei held a small gain in intraday dealing while the broader Topix slipped, and Hong Kong led the region with Hang Seng futures firmer. South Korean markets were closed for Liberation Day, which removes one of the region’s two largest cash markets from the session.Asia
  • Oil — Brent finished Friday at $88.52 a barrel and West Texas at $82.40, both more than five per cent higher on the week. Crude has been treading water since, with the weekend’s shipping disruption offset by the absence of any new escalation.Commodities
Japan: the number and the rate question
  • Growth — Second-quarter gross domestic product expanded at an annualised 1.1%, against the 2.0% economists had forecast, or 0.3% against the prior quarter. Exports carried the number, helped as much by a weak currency as by shipment volumes.Macro
  • The weak line — Capital spending fell 1.2% quarter on quarter, reversing an expected 0.4% gain. Domestic demand, not trade, is where the miss sits, and domestic demand is precisely the leg the Bank of Japan has leaned on to justify further normalisation.Macro
  • The policy bind — The policy rate has been at 1.0% since the July meeting, and the government has signalled support for a further increase in the near term. A growth print at half the expected pace does not remove that intention, but it complicates the argument for moving in September rather than October.Central banks
  • Bonds — Japanese government bond yields climbed as traders weighed hike expectations alongside the fiscal outlook, while the yen edged higher as Federal Reserve tightening bets receded. The two moves have opposite sources and the same direction.Rates
Hormuz: traffic rather than headlines
  • The count — Five commodity vessels transited the strait on Saturday and none were registered for Sunday, according to shiptracking data compiled by Kpler, against 31 across the prior weekend. Before the war began in February, more than 130 ships a day passed through.Geopolitics
  • The cause — The near-standstill followed the United Arab Emirates saying three vessels operated by the Abu Dhabi National Oil Company had been attacked in transit during the week. Owners are choosing not to sail rather than being unable to.Geopolitics
  • The talks — United States and Iranian negotiations remain stalled. Tehran’s position is that the naval blockade must be lifted before the strait fully reopens; Washington’s is that reopening comes first. Neither side moved over the weekend.Geopolitics
Rates, dollar and metals
  • The path — Bets on a Federal Reserve increase eased again overnight, the dollar dipped and Treasuries firmed, extending the move that began with Friday’s consumer data. Goldman Sachs argued in a note that market pricing has become too hawkish on the prospect of hikes.Rates
  • The level — The ten-year Treasury par yield was 4.63% on August 13, the most recent published constant-maturity reading. The curve has been steepening, which is why this week’s twenty-year auction is being watched as a demand test rather than a formality.Rates
  • Gold — Bullion traded near $4,400 an ounce after a second consecutive weekly advance, with the softer dollar following the retail sales miss doing most of the work. Gold is behaving as a rate-path instrument here more than a haven one.Commodities
  • Copper — London Metal Exchange copper pushed toward a record as supply tensions built. In a related signal, Korea Eximbank agreed to lend $1 billion to Glencore against copper supply, which is financing structured around scarcity rather than price.Commodities
China: the release moved
  • Timing — Industrial output, retail sales, fixed-asset investment and property prices were shifted to a 3 p.m. Beijing release, with the State Council briefing at the same hour, rather than the customary morning slot. The change puts the month’s heaviest data into the Asian afternoon.Macro
  • The context — July credit was already weak, with new yuan loans contracting and aggregate financing growth easing to 7.4%. The activity figures decide whether that reflects demand or seasonal distortion, which in turn shapes expectations for further support.Macro
The week’s fixed points
  • Wednesday — Minutes of the July Federal Open Market Committee meeting publish at 2 p.m. New York time. They describe a committee that met before the July retail sales figure and the August sentiment reading, which limits what they can settle about the current stance.Central banks
  • The retail run — Home Depot reports Tuesday, Target and Lowe’s Wednesday, Walmart Thursday. Friday’s $763.6 billion advance estimate was 0.6% lower on the month but 5.0% higher on the year, and the composition of these four results is what separates a weaker consumer from a consumer spending differently.Earnings
  • Supply — A twenty-year Treasury sale tests appetite at the long end while the curve steepens. Auctions have become an event again in a year when issuance and duration risk are moving in the same direction.Rates
  • Friday — Flash manufacturing and services surveys for the United States, the euro area and the United Kingdom land alongside Japanese inflation. They are the first read on August activity and therefore carry more weight than a minutes release describing July.Macro
Company board
  • Defence — The Pentagon is increasing ballistic missile production, putting the prime contractors in focus. $LMT closed Friday at $608.68 and $NOC at $585.87, both around two per cent higher on the session, with $LHX up 1.16%.Defense
  • WuXi AppTec — The contract research and manufacturing group has doubled this year on its position in the manufacturing chain for GLP-1 medicines, a reminder that the profitable part of an obesity-drug cycle is not always the company holding the patent.Biotech
  • AI capex — Large institutional investors are rotating toward the second tier of artificial intelligence beneficiaries as anxiety over capital spending recedes, while roughly $70 billion of off-balance-sheet credit support for AI borrowers is drawing scrutiny in the bond market.Technology
  • Allocation — Emerging markets drew fresh allocations as investors diversified away from a concentrated American index, and Harvard’s endowment disclosed a $2.2 billion position in SpaceX, one of the largest single private holdings taken by a university fund.Flows
Bottom line
  • The setup — Nothing that moves a market broke over the weekend, but two measurable things changed: Japanese growth undershot by half, and Hormuz traffic went to effectively zero. Both argue for slower global demand, and both push in the same direction as Friday’s American consumer data.Summary
  • What settles it — The Chinese activity figures this afternoon and the retail results between Tuesday and Thursday carry more information than Wednesday’s minutes, which describe a committee working from data that has since moved. The week is a sequence of reads on demand rather than a single event.Summary
Read the full Daily BriefingRead the Weekly Market Pulse

Biotech Catalyst Calendar 2026

Last updated: 22 July 2026

Merlintrader tracks upcoming biotech catalysts for U.S.-listed companies, including PDUFA dates, FDA decisions, clinical-trial readouts, advisory committee meetings and other regulatory milestones. Alongside each date you will find the source, company context and the key risks that can move the stock, plus links to deeper Merlintrader research when it is available. The focus is educational and risk-aware, with particular attention to small and mid-cap biotech names, where catalyst timing, cash runway and dilution risk can drive sharp moves in volatility. Dates can change and FDA decisions can arrive early or late, so always confirm an event against company filings and regulatory sources before acting on it.

Listed / exchange-traded biotech focus

Weekly Biotech Catalyst Tracker

Window covered: August 8 → September 30, 2026. Compact homepage board for unresolved FDA decisions, regulatory submissions and major clinical readouts. A prior-date item remains visible only when the regulatory process is still materially open. October and later events are excluded from this widget.

35Active
18FDA / Reg
17Data / Filing
Aug 14Updated
FDA / PDUFA Clinical data Filing watch High risk Large cap
$NRXPKETAFREEOngoingFDA reviewFirst-cycle review complete; vial certification remains

NRx Pharmaceuticals. The July 29 GDUFA goal date has passed, but the file is no longer accurately described as having “no outcome.” On August 7, NRx reported that FDA completed the first-cycle review of the ANDA for preservative-free intravenous ketamine with no major deficiencies related to the drug product, ingredients, proposed labeling, CMC or other drug-related matters. One major deficiency remains tied to the container-closure system: manufacturer certification concerning the luer-lock vial tip. Following an August 6 clarification meeting, FDA requested signed documentation and, according to the company, intends to review it in the shortest applicable cycle. No new exact action date has been disclosed.

$REGNgaretosmabAugBLAPriority Review in adult FOP

Regeneron. The BLA for garetosmab in adults with fibrodysplasia ossificans progressiva remains under Priority Review. Regeneron continues to guide to an FDA decision in August 2026 without disclosing an exact day.

$LNTHTAUKLARIFYAug 14ApprovedFDA approves the tau PET imaging agent in Alzheimer’s disease

Lantheus. FDA approved TAUKLARIFY (florquinitau F 18 injection), previously known as MK-6240, on August 14, 2026, the day after the PDUFA target date. The agent is indicated for PET imaging of the brain in adults with cognitive impairment being evaluated for Alzheimer’s disease, to identify patients with tau neurofibrillary tangle pathology. Safety and effectiveness have not been established for non-Alzheimer’s tauopathies. Approval is supported by two blinded-read studies covering more than 500 subjects: positive percent agreement ran from 80% to 88% and negative percent agreement from 98% to 99% in Study 1 (n=279), and from 68% to 82% and 93% to 99% in Study 2 (n=338). Lantheus intends to keep supporting Alzheimer’s therapeutic programs through its Pharma Solutions business while assessing the path toward broader commercial availability, so launch timing, coding and reimbursement remain open rather than settled.

$BMYiberdomide comboAug 17NDARRMM · iberdomide + daratumumab/dexamethasone

Bristol Myers Squibb. Priority Review PDUFA for iberdomide combined with daratumumab and dexamethasone in relapsed or refractory multiple myeloma. The application also has Breakthrough Therapy Designation for this indication.

$CAPRderamiocelAug 22Extreme riskPDUFA after 9–3 negative AdCom efficacy vote

Capricor. The resubmitted BLA for deramiocel in Duchenne muscular dystrophy-associated cardiomyopathy remains formally under review with an August 22 action date. On July 29, the advisory committee voted 9–3 that the available evidence did not provide the required substantial evidence of effectiveness. FDA is not bound by the vote, but the negative panel result, disputes over endpoint interpretation and the prior CRL make this an exceptionally high-risk regulatory event.

$RAREDTX401Aug 23BLAGene therapy for GSDIa

Ultragenyx. Priority Review PDUFA for the DTX401 (pariglasgene brecaparvovec) BLA in glycogen storage disease type Ia. The company reaffirmed the August 23 date in its August 4 update.

$JAZZZiihera comboAug 25sBLAFirst-line HER2-positive GEA

Jazz Pharmaceuticals. Priority Review PDUFA for the Ziihera (zanidatamab-hrii) sBLA in combination with chemotherapy, with or without tislelizumab, for first-line locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.

$GILDBIC/LENAug 27NDAOnce-daily oral HIV regimen

Gilead. Priority Review PDUFA for the bictegravir 75 mg/lenacapavir 50 mg NDA, a once-daily single-tablet regimen for virologically suppressed adults with HIV. This is a strategic lifecycle catalyst for the HIV franchise.

$PTGXrusfertideAugNDAPriority Review in polycythemia vera

Protagonist / Takeda. The rusfertide NDA in polycythemia vera is under Priority Review with a publicly disclosed August 2026 PDUFA goal month. Because no independently verifiable exact day has been published, this board correctly shows the month only.

$TLXPixclaraSep 11NDAPET imaging in glioma

Telix Pharmaceuticals. PDUFA target date for the resubmitted Pixclara (TLX101-Px) NDA. The PET imaging agent is intended to help characterize suspected recurrent or progressive glioma versus treatment-related changes.

$RAREUX111Sep 19BLAGene therapy for Sanfilippo syndrome type A

Ultragenyx. PDUFA for the resubmitted UX111 (rebisufligene etisparvovec) BLA in Sanfilippo syndrome type A. The company reaffirmed September 19 in its August 4 update; the application seeks accelerated approval.

$MRKWINREVAIRSep 21sBLAPAH · HYPERION-based label update

Merck. PDUFA for an sBLA seeking a U.S. label update for WINREVAIR (sotatercept-csrk) based on the Phase 3 HYPERION study in pulmonary arterial hypertension. Merck reaffirmed the September 21 date with its second-quarter results.

$IONSzilganersenSep 22NDAAlexander disease

Ionis. Priority Review PDUFA for the zilganersen NDA in Alexander disease, a rare progressive neurological disorder. It remains one of September’s most closely watched rare-disease regulatory catalysts.

$GRALGalleriSep 23FDA panelAdCom on the multi-cancer MCED test PMA

GRAIL. FDA’s Molecular and Clinical Genetics Panel will meet on September 23 to discuss and vote on the Galleri premarket approval application. Galleri is a blood-based multi-cancer early detection test proposed for screening adults aged 50 and older. This is not a drug PDUFA; it is a device and diagnostics regulatory catalyst that is nevertheless material to the stock.

$MIRMzilurgisertibSep 26NDAFOP · patients aged 12 and older

Mirum Pharmaceuticals / Incyte. Priority Review PDUFA for the zilurgisertib NDA in fibrodysplasia ossificans progressiva in patients aged 12 years and older. Mirum holds exclusive worldwide rights under license from Incyte.

$BFRIAmeluz PDTSep 28sNDAExpansion into superficial BCC

Biofrontera. PDUFA for the Ameluz photodynamic-therapy sNDA in superficial basal cell carcinoma. FDA completed its filing review without identifying filing deficiencies and assigned September 28 as the target action date.

$SRRKapitegromabSep 30BLASMA · review continues with second fill-finish site

Scholar Rock. The apitegromab BLA in spinal muscular atrophy remains targeted to September 30. On August 7, the company said that, in coordination with FDA, Catalent Indiana is being removed from the BLA and review is continuing using the second fill-finish facility; the related data package is under review. CMC and manufacturing risk therefore remain central, while the company continues to state that the action date is unchanged.

$ROIVbrepocitinibQ3NDADermatomyositis · Priority Review

Priovant / Roivant. The brepocitinib NDA in dermatomyositis is under Priority Review. The company has disclosed a PDUFA target action date in the third quarter of 2026 and, if approved, has pointed to a possible U.S. launch around the end of September. No exact PDUFA day has been made public.

$QUREAMT-130Q3BLAAccelerated-approval BLA filing in Huntington’s disease

uniQure. The company is preparing an AMT-130 BLA in Huntington’s disease after alignment with FDA on a pathway that may use comparison with an external control as the primary basis of the application. The submission remains a Q3 2026 catalyst; it is not a PDUFA, and FDA filing acceptance would be the next formal step.

$SLNdivesiranAugDataSANRECO Phase 2 in polycythemia vera

Silence Therapeutics. Phase 2 SANRECO topline data for divesiran in polycythemia vera are expected in August. The readout also provides a particularly relevant class comparison with rusfertide from $PTGX / Takeda.

$TENXTNX-103AugPhase 3Registrational LEVEL study · PH-HFpEF

Tenax Therapeutics. Topline results from the registrational Phase 3 LEVEL study of TNX-103, oral levosimendan, in pulmonary hypertension associated with heart failure with preserved ejection fraction are expected in August 2026. The results are also scheduled for a Late-Breaking Clinical Science presentation at ESC on August 29.

$EYPTDURAVYU / LUGANOAugPhase 3Pivotal wet AMD topline

EyePoint. Phase 3 LUGANO topline data for DURAVYU (vorolanib intravitreal insert) in wet age-related macular degeneration are expected in August 2026. LUGANO is the first of two fully enrolled global pivotal trials comparing six-month DURAVYU dosing with on-label aflibercept; LUCIA is expected to read out in the fourth quarter. Key variables include visual-acuity noninferiority, supplemental anti-VEGF use, anatomy and ocular safety.

$IMMXNXC-201Late SepDataNEXICART-2 · AL amyloidosis

Immix Biopharma. The next NEXICART-2 update for NXC-201 in relapsed or refractory AL amyloidosis is expected in late September 2026. The program is designed as BLA-enabling/registrational, and subsequent follow-up is expected to contribute to the regulatory path.

$KPTIselinexor comboAugsNDASelinexor + ruxolitinib filing in myelofibrosis

Karyopharm. The former XPORT-EC-042 endometrial-cancer catalyst is resolved: on July 30, the study did not meet its primary progression-free-survival endpoint. The active event is now the sNDA the company plans to submit in August for selinexor combined with ruxolitinib in myelofibrosis, with a request for Priority Review.

$KODDAYBREAKSepPhase 3Wet AMD · Zenkuda and KSI-501

Kodiak Sciences. One-year primary-endpoint topline results from the Phase 3 DAYBREAK study in wet age-related macular degeneration are expected in September 2026. The study evaluates Zenkuda (tarcocimab tedromer) and KSI-501 in parallel against aflibercept.

$ALMSenvudeucitinibQ3DataLUMUS Phase 2b in SLE

Alumis. Phase 2b LUMUS results for envudeucitinib in systemic lupus erythematosus are expected in the third quarter. For an autoimmune readout, the market will assess not only statistical significance but also dose consistency, clinical endpoints and the safety profile.

$IVVDVYD2311Q3DataDECLARATION pivotal study

Invivyd. Topline data from the pivotal Phase 3 DECLARATION study of VYD2311 are expected in the third quarter of 2026. The timing remains company guidance rather than a calendar-specific date.

$AMLXavexitideLate Aug / early SepPhase 3Pivotal LUCIDITY study in PBH

Amylyx. Topline results from the pivotal Phase 3 LUCIDITY study of avexitide in post-bariatric hypoglycemia are now expected in late August or early September 2026. The last participant has completed the final visit in the double-blind treatment period.

$PHVSdeucrictibant XRQ3Phase 3CHAPTER-3 · HAE prophylaxis

Pharvaris. Phase 3 CHAPTER-3 topline data for extended-release deucrictibant in hereditary-angioedema prophylaxis remain expected in the third quarter of 2026. This is one of the quarter’s most important registrational HAE readouts.

$SYRESPY003SepDataSKYLINE Phase 2 in ulcerative colitis

Spyre Therapeutics. SPY003 Part A topline data from the Phase 2 SKYLINE study in ulcerative colitis are expected in September 2026, according to the company’s August 4 update.

$VERATRUTAKNA / ataciceptQ3eGFRORIGIN 3 confirmatory follow-up

Vera Therapeutics. The ORIGIN 3 eGFR analysis is expected in the third quarter following accelerated approval of atacicept. This is not another approval decision; its significance lies in the durability of the renal effect and the read-through for the confirmatory pathway.

$XENEazetukalnerQ3NDAFocal-onset seizure filing

Xenon. The azetukalner NDA submission in focal-onset seizures remains on track for the third quarter. Filing confirmation would begin FDA’s filing-review stage and set up a later PDUFA assignment.

$BBIOinfigratinibQ3NDAAchondroplasia filing

BridgeBio. The company intends to submit the infigratinib NDA in achondroplasia in the third quarter. The immediate catalyst is the submission; FDA acceptance and any PDUFA date would follow.

$CLNNCNM-Au8Q3NDAAccelerated pathway in ALS

Clene. The company continues to target a third-quarter NDA submission for CNM-Au8 in amyotrophic lateral sclerosis through an accelerated-approval pathway. Regulatory risk remains high: a planned submission is not the same as FDA filing acceptance or approval.

$MLTXsonelokimabLate SepBLAHidradenitis suppurativa filing

MoonLake. The sonelokimab BLA submission in hidradenitis suppurativa is expected around the end of September 2026. FDA filing acceptance would create the next formal regulatory event.

Most attention-worthy watchlist

$NRXP$CAPR$RARE$PTGX$IONS$GRAL$MIRM$SRRK$TENX$EYPT$AMLX$PHVS$QURE$IMMX

Board rule

Only future or still materially unresolved catalysts through September are shown. $LNTH is the single resolved event kept for this update cycle, because FDA approved TAUKLARIFY on August 14, 2026, the day after its PDUFA target date. $NRXP remains because first-cycle review of the KETAFREE ANDA ended with a residual container-closure certification request and no new exact action date. $SVRA has been removed because FDA extended the MOLBREEVI PDUFA date to November 22, 2026, outside this board. Resolved events for $REPL, $MRNA, $BIIB and $GSK/zidesamtinib have been removed, as have $MPLT’s completed ZEPHYR readout and the former Q3 $OCGN items now guided to 2027. For $KPTI, the completed endometrial-cancer readout has been replaced by the planned August myelofibrosis sNDA. The September 23 $GRAL/Galleri panel and the August $TENX LEVEL and $EYPT LUGANO readouts are included. Month-only and quarter-only windows reflect disclosed company guidance and are not exact FDA dates.

Educational content only — not investment advice or a recommendation to buy or sell securities. Verify dates and primary filings before trading around binary events.Full catalyst calendarFDASEC EDGAR

Biotech Catalyst Lookup

Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.

Disclaimer. This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security, in line with SEC (USA) guidance. Data is generated by AI from web sources and may contain errors or be out of date — always verify against the linked primary source. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.